NEW YORK (GenomeWeb News) – The Montreal Heart Institute has partnered with several biotech companies and the Quebec government to launch a C$49.2 million (US$44.6 million) research program to that will use genetic and other biomarkers to develop personalized treatments for cardiovascular diseases.
In the project, dubbed ARTERIA, investigators at MHI's Research Centre and the industry partners will use biomarkers to optimize treatments for CVD that target low-density and high-density lipoproteins, vascular inflammation, and heart rate, MHI said today.